In addition, only a moderate reduction in the time-to-relapse was observed in patients expressing higher levels of TSPAN32 when MS patients were divided into two groups on the basis of their level of TSPAN32 expression in PBMC (referred as High and Low TSPAN32). This evidence concerns the gene TSPAN32 and myeloid sarcoma.